D01.F Belite Bio, Inc
- Market cap
- EUR 5.64B
- P/E
- -
- P/B
- 8.09x
- ROE
- -14.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is D01.F undervalued?
Graham numberThe Graham number of Belite Bio, Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Belite Bio, Inc fundamental analysis
No fundamental analysis for Belite Bio, Inc yet.
Belite Bio, Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009,…
Full company profileBelite Bio, Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Belite Bio, Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.80M | -12.8M | -31.7M | -40.0M | -84.2M | -135M |
| EBITDA | - | -12.4M | -31.2M | -35.7M | -77.1M | -135M |
| Net Income | -9.67M | -12.6M | -31.6M | -36.1M | -77.6M | -111M |
| EPS | -0.40 | -0.51 | -1.09 | -1.14 | -1.97 | -2.75 |
| Balance Sheet | ||||||
| Total Assets | 18.3M | 44.3M | 94.6M | 152M | 781M | 792M |
| Total Liabilities | 33.4M | 2.77M | 4.21M | 6.31M | 10.1M | 14.9M |
| Shareholders' Equity | -15.1M | 41.5M | 90.4M | 146M | 770M | 777M |
| Cash & Short-term Investments | 17.3M | 42.1M | 88.2M | 31.7M | 353M | - |
| Cash Flow | ||||||
| Operating Cash Flow | -7.47M | -11.5M | -29.8M | -29.2M | -37.0M | - |
| Capital Expenditure | 74.0K | 394K | 63.0K | 151K | 178K | 0.00 |
| Free Cash Flow | -7.55M | -11.9M | -29.9M | -29.4M | -37.2M | - |
| Ratios | ||||||
| ROE | - | -30.5% | -35.0% | -24.8% | -10.1% | -14.3% |
| ROA | -52.7% | -28.6% | -33.4% | -23.8% | -9.9% | -14.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Belite Bio, Inc dividends
Belite Bio, Inc has not paid dividends in the last 5 fiscal years.
Who owns Belite Bio, Inc
- Insiders 43.70%
- Institutions 24.34%
- Public & others 31.96%
- Shares outstanding 40.3M
- Free float 19.5M
Belite Bio, Inc company profile
- Company name
- Belite Bio, Inc
- Ticker
- D01.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Fiscal year end
- December
- Address
- 12750 High Bluff Drive, San Diego, CA, United States, 92130
- Phone
- 858 246 6240
- Website
- belitebio.com
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Belite Bio, Inc management
5- Dr. Yu-Hsin Lin M.B.A., Ph.D.Chairman of the Board of Directors & CEO · born 1978
- Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A.CFO & Director · born 1984
- Dr. Nathan L. Mata Ph.D.Chief Scientific Officer · born 1966
- Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D.Chief Medical Officer · born 1969
- Ms. Kelly KilpatrickChief Commercial Officer